AMPH vs BHC Stock Comparison

Amphastar Pharmaceuticals and Bausch Health Companies Prices as of Nov 13, 2026 Peers: Industry group

Head to Head

10 decided of 12

Bausch Health Companies leads on 5 of the 12 questions below (Bausch Health Companies 5, Amphastar Pharmaceuticals 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionAMPHBHCLeader
Larger companyMarket capitalisation $1.26B $3.18B BHC
Cheaper on earningsLower P/E, profitable companies only 12.7x -3.8x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 8.8x 1.6x BHC
Faster revenue growthRevenue growth, trailing twelve months +3.1% +10.8% BHC
More profitableNet margin, trailing twelve months 13.3% -7.6% AMPH
Better return on capitalReturn on invested capital 7.6% 6.4% AMPH
Less leveragedLower net debt / EBITDA 7.5x 7.4x BHC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +11.4% +26.1% BHC
Better 5-year returnAnnualised price return, 5 years +6.6%/yr -20.6%/yr AMPH
Less volatileAnnualised volatility, 1 year 53.3% 59.5% AMPH
Higher overall scoreMean of the five percentile scores vs peers 72/100 65/100 AMPH

Percentile Scorecard

AMPHBHC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisAMPHBHC
Valuation 98 #13 of 660 99 #6 of 660
Growth 41 #366 of 619 57 #265 of 619
Profitability 87 #78 of 595 86 #83 of 595
Financial Health 35 #443 of 683 16 #577 of 683
Shareholder Returns 98 #12 of 459 –
Overall 72 65
  • AMPH ranked among 695 companies in Pharmaceuticals and Biotechnology
  • BHC ranked among 695 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodAMPHBHCSPY
1 month +12.6%+41.8% -2.0%
3 months +40.5%+28.3% -2.8%
6 months +74.1%+54.1% +2.0%
Year to date +9.7%+20.1% +10.6%
1 year +11.4%+26.1% +12.2%
3 years -47.8%+23.0% +68.1%
3 years, per year -19.5%+7.1% +18.9%
5 years +37.9%-68.4% +61.4%
5 years, per year +6.6%-20.6% +10.1%
10 years +40.3%-53.6% +248.5%
10 years, per year +3.4%-7.4% +13.3%

Risk

MeasureAMPHBHCSPY
Volatility, 1Y 53.3%59.5% 13.6%
Downside volatility, 1Y 66.0%48.9% 13.9%
Beta vs S&P 500, 1Y 0.431.02 1.00
Return / volatility, 1Y 0.210.44 0.90
Max drawdown, 5Y -74.0%-84.7% -25.4%
From 52-week high -0.1%-6.1% -3.2%
52-week high $29.40$8.89 $779.14
52-week low $16.87$4.43 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleAMPHBHC
P/E now vs peer median 12.6xmedian 17.0x -3.7xmedian 17.0x
P/S now vs peer median 1.7xmedian 8.4x 0.3xmedian 8.4x
EV/EBITDA now vs peer median 32.2xmedian 14.6x 8.6xmedian 14.6x
P/FCF now vs peer median 9.0xmedian 19.0x 1.7xmedian 19.0x
P/B now vs peer median 1.5xmedian 2.0x -2.4xmedian 2.0x
PEG now vs peer median -4.05median 0.43 -0.65median 0.43

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsAMPHBHC
Revenue $745.79M $11.11B
Gross profit $349.09M $8.07B
Operating income $139.74M $1.25B
Net income $98.96M -$837.00M
Free cash flow $139.02M $1.87B
R&D $92.29M $638.00M
EPS (diluted) $2.28 $-2.21
Cash & equivalents $204.59M $2.49B
Total debt $613.00M $20.64B
Shares (diluted) 43.38M 380.70M
Enterprise value $163.54M -$3.74B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricAMPHBHC
P/E 12.6x -3.7x
P/FCF 9.0x 1.7x
P/Operating cash flow 7.1x 1.4x
P/S 1.7x 0.3x
P/B 1.5x -2.4x
P/Tangible book 1.6x -0.6x
EV/EBITDA 32.2x 8.6x
EV/EBIT 11.7x 17.1x
EV/Revenue 2.2x 1.9x
EV/FCF 11.8x 11.4x
EV/Operating cash flow 9.3x 9.6x
PEG (3Y EPS CAGR) -4.05 -0.65

Growth

14 metrics
MetricAMPHBHC
Revenue growth (1Y) 3.1% 10.8%
Revenue CAGR (3Y) 7.4% 9.2%
Gross profit growth (1Y) -2.2% 13.9%
Gross profit CAGR (3Y) 2.3% 10.2%
Operating income growth (1Y) -6.8% -34.3%
Operating income CAGR (3Y) -8.2% 50.6%
Net income growth (1Y) -11.3% -345.5%
Net income CAGR (3Y) -9.9% 5.3%
EPS growth (1Y) -2.6% -329.1%
EPS CAGR (3Y) -3.1% 5.7%
Operating cash flow growth (1Y) 15.1% 46.7%
Operating cash flow CAGR (3Y) 0.1% 25.5%
Free cash flow growth (1Y) 22.7% 70.3%
Free cash flow CAGR (3Y) -0.2% 25.9%

Profitability

14 metrics
MetricAMPHBHC
Gross margin 46.8% 72.6%
EBITDA margin 6.8% 22.2%
Operating margin 18.7% 11.2%
Pretax margin 17.4% -3.2%
Net margin 13.3% -7.6%
FCF margin 18.6% 16.8%
Operating cash flow margin 23.5% 19.9%
Return on equity 12.5% –
Return on assets 5.7% -3.3%
Return on invested capital 7.6% 6.4%
Return on capital employed 9.0% 6.1%
Asset turnover 0.4x 0.4x
Cash conversion (OCF / net income) 1.8x -2.6x
Stock comp / revenue 4.0% 2.2%

Financial Health

11 metrics
MetricAMPHBHC
Debt / assets 35.8% 81.0%
Debt / equity 0.8x -15.5x
Net debt / EBITDA 7.5x 7.4x
Debt / FCF 4.4x 11.1x
Liabilities / assets 52.4% 105.2%
Equity / assets 47.6% -5.2%
Interest coverage 5.3x 0.8x
Current ratio 3.3x 1.6x
Quick ratio 2.3x 1.1x
Cash ratio 1.3x 0.5x
Altman Z-score 2.44 0.22

Shareholder Returns

7 metrics
MetricAMPHBHC
Dividend yield – –
Net buyback yield 7.2% –
Shareholder yield 7.2% 0.0%
Payout ratio (earnings) – –
Payout ratio (FCF) – –
Dividend growth (1Y) – –
Dividend CAGR (3Y) – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusAMPHBHC
Forward P/E 8.8xFY2026 1.6xFY2026
EPS, next fiscal year $3.34FY2026 $5.23FY2026
EPS growth, next FY +2.8%FY2026 +36.6%FY2026
EPS growth, the year after +6.9% -20.3%
Revenue, next fiscal year $802.03MFY2026 $11.31BFY2026
Revenue growth, next FY +11.4%FY2026 +10.6%FY2026
Revenue growth, the year after -5.7% -1.5%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersAMPHBHC
Held by institutions 64.8% 63.3%
Institutions holding 209 221
Change in shares held, QoQ -11.7% +1.9%
Institutions buying 96 99
Institutions selling 74 63
Buyers to sellers 1.30 1.57

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

AMPHBHC
AMPH 1.00 0.18
BHC 0.18 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, AMPH and BHC?

Bausch Health Companies (BHC) is the largest by market capitalisation: Amphastar Pharmaceuticals (AMPH) $1.26B, Bausch Health Companies (BHC) $3.18B.

Which company is growing faster?

Bausch Health Companies (BHC) grew revenue fastest over the trailing twelve months: Amphastar Pharmaceuticals (AMPH) +3.1%, Bausch Health Companies (BHC) +10.8%.

Which company is more profitable?

Amphastar Pharmaceuticals (AMPH) has the highest net margin (Amphastar Pharmaceuticals (AMPH) 13.3%, Bausch Health Companies (BHC) -7.6%). On return on invested capital, Amphastar Pharmaceuticals (AMPH) leads (Amphastar Pharmaceuticals (AMPH) 7.6%, Bausch Health Companies (BHC) 6.4%).

Which stock has performed better?

Over the past year Bausch Health Companies (BHC) returned the most: Amphastar Pharmaceuticals (AMPH) +11.4%, Bausch Health Companies (BHC) +26.1%. Over five years, Amphastar Pharmaceuticals (AMPH) compounded fastest (Amphastar Pharmaceuticals (AMPH) +6.6%/yr, Bausch Health Companies (BHC) -20.6%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Amphastar Pharmaceuticals (AMPH) has been the steadiest (Amphastar Pharmaceuticals (AMPH) 53.3%, Bausch Health Companies (BHC) 59.5%). Volatility measures how widely the price swings, not the risk of the business.

Do AMPH and BHC move together?

Their daily returns over the past year have a correlation of 0.18, a weak relationship. Holding both diversifies more than two closely linked stocks would.

Which is the better stock, AMPH and BHC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Bausch Health Companies (BHC) leads on 5. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.